Design, Synthesis, and Biological Evaluation of 2-Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors

被引:4
作者
Deng, Minjie [1 ]
Wang, Peipei [2 ]
Long, Xiubing [3 ]
Xu, Gaoya [2 ]
Wang, Chang [5 ]
Li, Jia [2 ,5 ,6 ]
Zhou, Yubo [2 ,4 ,5 ]
Liu, Tao [1 ,7 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, ENS Joint Lab Med Chem, ZJU, Hangzhou 310058, Peoples R China
[2] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[3] Wuxi Apptec Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China
[4] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Peoples R China
[7] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Hangzhou 310058, Peoples R China
基金
中国国家自然科学基金;
关键词
2-aminothiazole; CHK1; inhibitors; antiproliferation; hematologic malignancies; biological activity;
D O I
10.1002/cmdc.202200664
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 2-aminothiazole derivatives were designed, synthesized on the basis of bioisosterism strategy and evaluated for their CHK1 inhibitory activity. Most of them exhibited potent CHK1 inhibition, and excellent antiproliferative activity against MV-4-11 and Z-138 cell lines. Systematic structure-activity relationship (SAR) efforts led to the discovery of a promising compound 8 n, which showed potent CHK1 inhibitory activity with IC50 value of 4.25 +/- 0.10 nM, excellent antiproliferative activity against MV-4-11 and Z-138 cells with IC50 value of 42.10 +/- 5.77 nM and 24.16 +/- 6.67 nM, respectively, as well as moderate oral exposure (AUC((0-t))=1076.25 h center dot ng/mL) in mice. Additionally, treatment of MV-4-11 cells with compound 8 n for 2 h led to robust inhibition of CHK1 autophosphorylation on serine 296. Furthermore, kinase selectivity assay revealed that 8 n displayed acceptable selectivity toward 15 kinases. These results demonstrated that compound 8 n may be a promising potential anticancer agent for further development.
引用
收藏
页数:18
相关论文
共 13 条
  • [1] DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system
    Clarke, CAL
    Clarke, PR
    [J]. BIOCHEMICAL JOURNAL, 2005, 388 : 705 - 712
  • [2] New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
    Dai, Yun
    Grant, Steven
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (02) : 376 - 383
  • [3] The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
    Di Tullio, Alessandro
    Rouault-Pierre, Kevin
    Abarrategi, Ander
    Mian, Syed
    Grey, William
    Gribben, John
    Stewart, Aengus
    Blackwood, Elizabeth
    Bonnet, Dominique
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [4] Joseph S., 2015, [No title captured], Patent No. 29067920
  • [5] LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
    King, Constance
    Diaz, H. Bruce
    McNeely, Samuel
    Barnard, Darlene
    Dempsey, Jack
    Blosser, Wayne
    Beckmann, Richard
    Barda, David
    Marshall, Mark S.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (09) : 2004 - 2013
  • [6] Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
    Kumar, Rajesh
    Harilal, Seetha
    Gupta, Sheeba Varghese
    Jose, Jobin
    Parambi, Della Grace Thomas
    Uddin, Md. Sahab
    Shah, Muhammad Ajmal
    Mathew, Bijo
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182
  • [7] Checkpoint kinase inhibitors: a patent review (2009-2010)
    Lainchbury, Michael
    Collins, Ian
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (08) : 1191 - 1210
  • [8] Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
    Osborne, James D.
    Matthews, Thomas P.
    McHardy, Tatiana
    Proisy, Nicolas
    Cheung, Kwai-Ming J.
    Lainchbury, Michael
    Brown, Nathan
    Walton, Michael I.
    Eve, Paul D.
    Boxall, Katherine J.
    Hayes, Angela
    Henley, Alan T.
    Valenti, Melanie R.
    Brandon, Alexis K. De Haven
    Box, Gary
    Jamin, Yann
    Robinson, Simon P.
    Westwood, Isaac M.
    van Montfort, Rob L. M.
    Leonard, Philip M.
    Lamers, Marieke B. A. C.
    Reader, John C.
    Aherne, G. Wynne
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Garrett, Michelle D.
    Collins, Ian
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (11) : 5221 - 5237
  • [9] The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer
    Smith, Joanne
    Tho, Lye Mun
    Xu, Naihan
    Gillespie, David A.
    [J]. ADVANCES IN CANCER RESEARCH, VOL 108, 2010, 108 : 73 - 112
  • [10] The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
    Sorensen, CS
    Hansen, LT
    Dziegielewski, J
    Syljuåsen, RG
    Lundin, C
    Bartek, J
    Helleday, T
    [J]. NATURE CELL BIOLOGY, 2005, 7 (02) : 195 - U121